Facebook
Twitter
LinkedIn
ForwardAdvances in the Management of Metastatic Breast Cancer with SABCS Updates
The treatment landscape of metastatic breast cancer is evolving constantly. The decision-making process for management of metastatic breast cancer (mBC) should involve careful consideration of the available evidence for selection of optimal therapy and a detailed discussion of the benefits and risks associated with all possible treatment strategies with patients. With expanding treatment options, clinicians are challenged to understand important criteria used in selecting optimal first- and subsequent-line therapies for individuals with metastatic breast cancer. Staying up-to-date with the available treatment options is important to integrate new evidence-based data into their clinical practice, and being familiar with their toxicity profiles is important to optimize patient outcomes.
Target Audience
This educational program is designed to meet the educational needs of physicians, nurse practitioners, nurses, PAs, pharmacists, and other health care professionals who manage patients with breast cancer.
Learning Objectives
Following this program, participants should be able to:
HR-Negative, HER2-Negative Metastatic Breast Cancer
- Describe the current therapeutic approaches for first-line management of metastatic HR-negative, HER2-negative metastatic breast cancer.
- Utilize evidence-based approaches to select first- and subsequent-line treatment options for patients with metastatic HR-negative, HER2-negative metastatic breast cancer.
- Outline new and emerging therapeutic options for HR-negative, HER2-negative metastatic breast cancer.
HR-Positive, HER2-Negative Metastatic Breast Cancer
- Select evidence-based first- and subsequent-line treatment options for patients with metastatic breast cancer based on HR- and HER2-receptor status.
- Review safety profile of agents used in management of metastatic HR-positive, HER2-negative metastatic breast cancer and recognize strategies to optimally manage common toxicities.
- Outline new and emerging therapeutic options for patients with metastatic breast cancer.
HER2-Positive Metastatic Breast Cancer
- Integrate recent advances and available clinical data to optimally select and sequence HER2-targeted agents in the treatment of HER2-positive metastatic breast cancer.
- Optimally manage common toxicities related to the HER2-targeted therapies.
- Review new and emerging therapeutic options for patients with HER2-positive metastatic breast cancer.
Chau T. Dang, MD
Memorial Sloan Kettering Cancer Center
William J. Gradishar, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Hatem Soliman, MD
Moffitt Cancer Center
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Definitions
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
Faculty Disclosures
The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Chau T. Dang, MD
Daiichi-Sankyo Co.: Consulting Fee
Gilead Sciences, Inc.: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee
Pfizer Inc.: Consulting Fee
Puma Biotechnology: Grant/Research Support
Roche/Genentech: Consulting Fee; Grant/Research Support
SeaGen: Consulting Fee
William J. Gradishar, MD (also a member of the Planning Committee)
AstraZeneca Pharmaceuticals LP: Honoraria; Scientific Advisor
Biotheronostics: Honoraria; Scientific Advisor
Daiichi-Sankyo co.: Honoraria; Scientific Advisor
Eli Lilly and Company: Scientific Advisor
ImmunoGen, Inc.: Honoraria; Scientific Advisor
MacroGenics: Scientific Advisor
Puma Biotechnology: Scientific Advisor
Seattle Genetics, Inc.: Scientific Advisor
Hatem Soliman, MD
Amgen Inc.: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Consulting Fee
Merck & Co., Inc.: Product/Speakers Bureau
Novartis Pharmaceuticals Corporation: Consulting Fee
Puma Biotechnology: Consulting Fee
SeaGen: Consulting Fee
Planning Committee and NCCN Staff Disclosures
None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
NCCN designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
NCCN designates this educational activity for a maximum of 1.25 contact hours.
Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.25 contact hours (0.125 CEUs) of continuing education credit. UAN: JA4008196-0000-23-025-H01-P
Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until March 15, 2024. PAs should only claim credit commensurate with the extent of their participation.
Available Credit
- 1.25 AAPA Category 1 CME credit
- 1.25 ACPE contact hours
- 1.25 AMA PRA Category 1 Credit™
- 1.25 ANCC contact hours
- 1.25 Participation
Price
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing